BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 20008221)

  • 21. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
    Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
    Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
    Knoechel B; Roderick JE; Williamson KE; Zhu J; Lohr JG; Cotton MJ; Gillespie SM; Fernandez D; Ku M; Wang H; Piccioni F; Silver SJ; Jain M; Pearson D; Kluk MJ; Ott CJ; Shultz LD; Brehm MA; Greiner DL; Gutierrez A; Stegmaier K; Kung AL; Root DE; Bradner JE; Aster JC; Kelliher MA; Bernstein BE
    Nat Genet; 2014 Apr; 46(4):364-70. PubMed ID: 24584072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
    Sanchez-Martin M; Ferrando A
    Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.
    Palomero T; Ferrando A
    Clin Cancer Res; 2008 Sep; 14(17):5314-7. PubMed ID: 18765521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors.
    Palomero T; Barnes KC; Real PJ; Glade Bender JL; Sulis ML; Murty VV; Colovai AI; Balbin M; Ferrando AA
    Leukemia; 2006 Jul; 20(7):1279-87. PubMed ID: 16688224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An activating intragenic deletion in NOTCH1 in human T-ALL.
    Haydu JE; De Keersmaecker K; Duff MK; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Ferrando A
    Blood; 2012 May; 119(22):5211-4. PubMed ID: 22510873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
    Tammam J; Ware C; Efferson C; O'Neil J; Rao S; Qu X; Gorenstein J; Angagaw M; Kim H; Kenific C; Kunii K; Leach KJ; Nikov G; Zhao J; Dai X; Hardwick J; Scott M; Winter C; Bristow L; Elbi C; Reilly JF; Look T; Draetta G; Van der Ploeg L; Kohl NE; Strack PR; Majumder PK
    Br J Pharmacol; 2009 Nov; 158(5):1183-95. PubMed ID: 19775282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines.
    Liu S; Breit S; Danckwardt S; Muckenthaler MU; Kulozik AE
    Ann Hematol; 2009 Jul; 88(7):613-21. PubMed ID: 19057901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
    Samon JB; Castillo-Martin M; Hadler M; Ambesi-Impiobato A; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Jakubczak J; Randolph S; Cordon-Cardo C; Ferrando AA
    Mol Cancer Ther; 2012 Jul; 11(7):1565-75. PubMed ID: 22504949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
    Sanda T; Li X; Gutierrez A; Ahn Y; Neuberg DS; O'Neil J; Strack PR; Winter CG; Winter SS; Larson RS; von Boehmer H; Look AT
    Blood; 2010 Mar; 115(9):1735-45. PubMed ID: 20007543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Notch Partners in the Long Journey of T-ALL Pathogenesis.
    Toribio ML; González-García S
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.
    Kindler T; Cornejo MG; Scholl C; Liu J; Leeman DS; Haydu JE; Fröhling S; Lee BH; Gilliland DG
    Blood; 2008 Oct; 112(8):3373-82. PubMed ID: 18663146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
    Pajcini KV; Xu L; Shao L; Petrovic J; Palasiewicz K; Ohtani Y; Bailis W; Lee C; Wertheim GB; Mani R; Muthusamy N; Li Y; Meijerink JPP; Blacklow SC; Faryabi RB; Cherry S; Pear WS
    Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
    Palomero T; Sulis ML; Cortina M; Real PJ; Barnes K; Ciofani M; Caparros E; Buteau J; Brown K; Perkins SL; Bhagat G; Agarwal AM; Basso G; Castillo M; Nagase S; Cordon-Cardo C; Parsons R; Zúñiga-Pflücker JC; Dominguez M; Ferrando AA
    Nat Med; 2007 Oct; 13(10):1203-10. PubMed ID: 17873882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
    Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
    J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia.
    Kaushik B; Pal D; Saha S
    Curr Drug Targets; 2021; 22(15):1789-1798. PubMed ID: 33538669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
    Chang YS; Gills JJ; Kawabata S; Onozawa M; Della Gatta G; Ferrando AA; Aplan PD; Dennis PA
    Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37800623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in research on childhood T-cell acute lymphocytic leukemia, Notch1 signaling pathway, and its inhibitors: A review.
    Fang-Fang Z; You Y; Wen-Jun L
    Bosn J Basic Med Sci; 2021 Apr; 21(2):136-144. PubMed ID: 32415821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Notch in T-ALL: new players in a complex disease.
    Koch U; Radtke F
    Trends Immunol; 2011 Sep; 32(9):434-42. PubMed ID: 21775206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
    Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
    Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.